MARKET

VECT

VECT

VectivBio Holding AG
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.50
-0.26
-1.89%
Closed 16:00 05/07 EDT
OPEN
13.77
PREV CLOSE
13.76
HIGH
14.07
LOW
13.20
VOLUME
41.44K
TURNOVER
--
52 WEEK HIGH
37.70
52 WEEK LOW
13.20
MARKET CAP
459.20M
P/E (TTM)
-7.6604
1D
5D
1M
3M
1Y
5Y
The Dementia Discovery Fund Appoints Luca Santarelli, M.D., a Proven Neuroscience Leader, as the New Chair of its Scientific Advisory Board
and , /PRNewswire/ -- The Dementia Discovery Fund (DDF), the venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias, announces the appointment of , M.D., as new Chair of its Scient...
PR Newswire - PRF · 3d ago
Quest upgraded while Teva downgraded at UBS, and VectiveBio scores two new buy initiations in today's analyst action
Growth beyond COVID for Quest DiagnosticsQuest Diagnostics (DGX) is poised for top-line growth even as COVID-19 testing wanes, according to UBS, which has upgraded shares from neutral to buy.Analyst Kevin
Seekingalpha · 4d ago
Credit Suisse Initiates Coverage On VectivBio Holding with Outperform Rating, Announces Price Target of $24
Credit Suisse analyst Tiago Fauth initiates coverage on VectivBio Holding (NASDAQ:VECT) with a Outperform rating and announces Price Target of $24.
Benzinga · 4d ago
B of A Securities Initiates Coverage On VectivBio Holding with Buy Rating, Announces Price Target of $19
B of A Securities initiates coverage on VectivBio Holding (NASDAQ:VECT) with a Buy rating and announces Price Target of $19.
Benzinga · 4d ago
--SVB Leerink Initiates Coverage on VectivBio With Outperform Rating, $28 Price Target
MT Newswires · 4d ago
--BofA Securities Initiates Coverage on VectivBio With Buy Rating, $19 Price Target
MT Newswires · 4d ago
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21)
Benzinga · 04/22 12:08
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Benzinga · 04/20 12:06
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VECT. Analyze the recent business situations of VectivBio Holding AG through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About VECT
VectivBio Holding AG is a holding company based in Switzerland. The Company trough it's subsidiaries operates as a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need.

Webull offers kinds of VectivBio Holding AG stock information, including NASDAQ:VECT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VECT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VECT stock methods without spending real money on the virtual paper trading platform.